Brooklyn Shares Owned by Insiders

BTX
 Stock
  

USD 0.56  0.04  7.69%   

Brooklyn Immunotherapeutics fundamentals help investors to digest information that contributes to Brooklyn Immunotherapeuti's financial success or failures. It also enables traders to predict the movement of Brooklyn Stock. The fundamental analysis module provides a way to measure Brooklyn Immunotherapeuti's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Brooklyn Immunotherapeuti stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Brooklyn Shares Owned by Insiders Analysis

Brooklyn Immunotherapeuti's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
 2021 2022 (projected)
Receivables4.6 K4.72 K
Inventories900923.68
Insiders Shares 
 = 
Executives Shares 
Employees 
More About Shares Owned by Insiders | All Equity Analysis

Current Brooklyn Immunotherapeuti Shares Owned by Insiders

    
  26.39 %  
Most of Brooklyn Immunotherapeuti's fundamental indicators, such as Shares Owned by Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Brooklyn Immunotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Brooklyn Shares Owned by Insiders Driver Correlations

Understanding the fundamental principles of building solid financial models for Brooklyn Immunotherapeuti is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Shares Owned by Insiders. Since Brooklyn Immunotherapeuti's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Brooklyn Immunotherapeuti's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Brooklyn Immunotherapeuti's interrelated accounts and indicators.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Compare to competition

Based on the latest financial disclosure, 26.39% of Brooklyn Immunotherapeutics are shares owned by insiders. This is 73.85% higher than that of the Healthcare sector and 86.11% higher than that of the Biotechnology industry. The shares owned by insiders for all United States stocks is 161.55% lower than that of the firm.

Brooklyn Immunotherapeuti Current Valuation Drivers

We derive many important indicators used in calculating different scores of Brooklyn Immunotherapeuti from analyzing Brooklyn Immunotherapeuti's financial statements. These drivers represent accounts that assess Brooklyn Immunotherapeuti's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Brooklyn Immunotherapeuti's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(210.27 K)(582.15 K)(212.89 K)(374.41 K)(430.57 K)(464.56 K)
Revenue Per Employee36.4 K63.14 K63.91 K33.11 K38.08 K52.38 K
Average Assets17.55 M15.62 M15.29 M8.94 M39.08 M42.17 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA1.8 M2.83 M1.4 M(7.19 M)(122.02 M)(125.23 M)
Earnings Before Interest Taxes and Depreciation Amortization USD1.8 M2.83 M1.4 M(7.19 M)(122.02 M)(125.23 M)
Earnings before Tax(1.01 M)(323 K)(2.02 M)(7.29 M)(122.48 M)(125.7 M)
Average Equity5.86 M6.39 M6.2 M3.48 M17.33 M18.69 M
Enterprise Value11.7 M6.81 M10.23 M8.31 M195.87 M211.33 M
Free Cash Flow(903 K)(214 K)1.65 M(8.14 M)(23.64 M)(24.26 M)
Invested Capital5.39 M9.38 M8.24 M9.01 M11.54 M10.79 M
Invested Capital Average5.34 M8.47 M11.74 M5.55 M10.2 M9.61 M
Market Capitalization10.61 M5.6 M6.38 M6.64 M217.02 M234.16 M
Tangible Asset Value14.11 M12.18 M11.51 M10.86 M29.48 M23.71 M
Working Capital(1.11 M)2.76 M(25 K)(1.39 M)15.09 M16.28 M

Brooklyn Fundamentals

About Brooklyn Immunotherapeuti Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Brooklyn Immunotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brooklyn Immunotherapeuti using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brooklyn Immunotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Brooklyn Immunotherapeuti operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 10 people.

Brooklyn Immunotherapeuti Investors Sentiment

The influence of Brooklyn Immunotherapeuti's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Brooklyn. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Brooklyn Immunotherapeuti's public news can be used to forecast risks associated with investment in Brooklyn. The trend in average sentiment can be used to explain how an investor holding Brooklyn can time the market purely based on public headlines and social activities around Brooklyn Immunotherapeutics. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Brooklyn Immunotherapeuti's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Brooklyn Immunotherapeuti's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Brooklyn Immunotherapeuti's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Brooklyn Immunotherapeuti.

Brooklyn Immunotherapeuti Implied Volatility

    
  96.97  
Brooklyn Immunotherapeuti's implied volatility exposes the market's sentiment of Brooklyn Immunotherapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Brooklyn Immunotherapeuti's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Brooklyn Immunotherapeuti stock will not fluctuate a lot when Brooklyn Immunotherapeuti's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Brooklyn Immunotherapeuti in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Brooklyn Immunotherapeuti's short interest history, or implied volatility extrapolated from Brooklyn Immunotherapeuti options trading.

Pair Trading with Brooklyn Immunotherapeuti

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brooklyn Immunotherapeuti position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brooklyn Immunotherapeuti will appreciate offsetting losses from the drop in the long position's value.

Moving together with Brooklyn Immunotherapeuti

0.73ACHVAchieve Life Sciences Earnings Call  TodayPairCorr
0.8ADTXAditxt Inc Earnings Call  TomorrowPairCorr

Moving against Brooklyn Immunotherapeuti

0.69ALTAltimmune Earnings Call  TodayPairCorr
0.51ARTLArtelo Biosciences SplitPairCorr
The ability to find closely correlated positions to Brooklyn Immunotherapeuti could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brooklyn Immunotherapeuti when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brooklyn Immunotherapeuti - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brooklyn Immunotherapeutics to buy it.
The correlation of Brooklyn Immunotherapeuti is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brooklyn Immunotherapeuti moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brooklyn Immunotherapeuti moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brooklyn Immunotherapeuti can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Brooklyn Immunotherapeuti Piotroski F Score and Brooklyn Immunotherapeuti Altman Z Score analysis. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
CEO Directory
Screen CEOs from public companies around the world
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
29.7 M
Return On Assets
-0.65
Return On Equity
-17.6
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.